Studies have shown a strong correlation between IBDs and the progression of CRC, and prior research has also suggested that early administration of TLR2 agonists may serve as an effective treatment strategy to impede tumor progression (Millar et al. 2022). This evidence concerns the gene TLR2 and colorectal carcinoma.